{"id":26620,"date":"2024-01-08T18:12:01","date_gmt":"2024-01-08T12:42:01","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26620"},"modified":"2025-09-26T11:04:59","modified_gmt":"2025-09-26T05:34:59","slug":"kras-inhibitors-beyond-g12c","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","title":{"rendered":"Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a07939e75995\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a07939e75995\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Epidemiological_Insights_into_Geographic_Distribution_of_KRAS_Mutations\" >Epidemiological Insights into Geographic Distribution of KRAS Mutations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#The_Therapeutic_Landscape_of_KRAS_Inhibitors_Progress_and_Promise\" >The Therapeutic Landscape of KRAS Inhibitors: Progress and Promise<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Advancing_Therapies_Clinical_Trials_for_KRAS_Inhibitors\" >Advancing Therapies: Clinical Trials for KRAS Inhibitors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#What_Lies_in_the_Future_Beyond_G12C\" >What Lies in the Future Beyond G12C?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Untapped_Potential_in_the_KRAS_Inhibitors_Market\" >Untapped Potential in the KRAS Inhibitors Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Conclusion_A_Glimpse_into_the_Future\" >Conclusion: A Glimpse into the Future<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like <strong>sotorasib and adagrasib<\/strong> directly target KRAS G12C by forming a bond with cysteine 12 in the KRAS-G12C protein\u2019s switch-II pocket. This action locks KRAS in an inactive state, halting cell proliferation. While inhibiting KRAS G12C proves effective against certain lung cancers, it doesn\u2019t impact PI3K signaling. This suggests that alternative pathways unrelated to KRAS-G12C might activate PI3K, contributing to resistance against G12C inhibitors and prompting the development of new therapies. G12C stands as the primary focus in KRAS targeting, yet newer studies reveal emerging targets like G12D, although their treatment paths are less established. Some companies are exploring PAN-KRAS inhibition as a novel treatment method. For instance, <strong>Onvansertib<\/strong>, currently in a Phase II trial for <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market\">metastatic colorectal cancer treatment<\/a>, aims to address all KRAS mutations by activating PLK1, which triggers RAS downstream pathways.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-epidemiological-insights-into-geographic-distribution-of-kras-mutations\"><span class=\"ez-toc-section\" id=\"Epidemiological_Insights_into_Geographic_Distribution_of_KRAS_Mutations\"><\/span><strong>Epidemiological Insights into Geographic Distribution of KRAS Mutations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The identification of KRAS mutation dates back to the 1980s, and it has since been recognized as a prevalent mutation in various cancers such as lung cancer, colorectal cancer, and pancreatic cancer. Among these, the G12C variant is the most widespread in non-small cell lung cancer (NSCLC) across the United States, Europe, and Japan, occurring in approximately <strong>25\u201330%<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">KRAS-mutated NSCLC patients<\/a>, as per DelveInsight analysis. Immunotherapy stands as the standard of care for individuals with KRAS-mutant NSCLC, especially those with G12C variations, as there are currently no authorized treatments specifically targeting this variant.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"1000\" height=\"234\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143336\/KRAS-Variants-in-NSCLC-in-the-United-States.png\" alt=\"KRAS Variants in NSCLC in the United States\" class=\"wp-image-26625\" style=\"width:750px;height:176px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143336\/KRAS-Variants-in-NSCLC-in-the-United-States.png 1000w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143336\/KRAS-Variants-in-NSCLC-in-the-United-States-300x70.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143336\/KRAS-Variants-in-NSCLC-in-the-United-States-150x35.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143336\/KRAS-Variants-in-NSCLC-in-the-United-States-768x180.png 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/figure>\n\n\n\n<p>In colorectal cancers, around <strong>45%<\/strong> exhibit KRAS mutations, with G12D being the predominant variant found in about <strong>25\u201335% <\/strong>of individuals with KRAS mutations. Despite G12D being the most common variant, the majority of <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">KRAS therapies for colorectal cancer<\/a> focus on G12C, despite its lower prevalence in this cancer type. Ongoing developments include limited treatments for G12D and PAN-KRAS variants.<\/p>\n\n\n\n<p>Pancreatic cancer, where KRAS mutations are present in <strong>60\u201390%<\/strong> of patients, sees G12D as the most frequent KRAS variant, occurring in approximately <strong>40\u201350%<\/strong> of KRAS-mutated patients. However, the development of effective \u201csystemic\u201d and \u201cbiomarker-specific\u201d therapies for pancreatic cancer patients remains a substantial unmet need. Recognizing this, several key players in the pharmaceutical and biotech industries are increasingly exploring the potential of targeting KRAS mutations in pancreatic cancer, seeing this relatively unexplored segment as a promising market opportunity for cancer treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-therapeutic-landscape-of-kras-inhibitors-progress-and-promise\"><span class=\"ez-toc-section\" id=\"The_Therapeutic_Landscape_of_KRAS_Inhibitors_Progress_and_Promise\"><\/span><strong>The Therapeutic Landscape of KRAS Inhibitors: Progress and Promise<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>LUMAKRAS<\/strong>, the first approved targeted <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-non-small-cell-lung-cancer-market\">treatment for NSCLC patients<\/a> with the KRAS G12C mutation, has been joined by <strong>Mirati\u2019s KRAZATI<\/strong> as the second approved therapy in this category. The primary distinctions between these two KRASG12C inhibitors lie in their CNS-specific activity and Duration of Response (DoR). KRAZATI demonstrates the ability to penetrate the central nervous system, hindering the proliferation of cancer cells within the brain, whereas there is currently insufficient evidence to suggest a similar outcome for LUMAKRAS. In terms of DoR, LUMAKRAS has exhibited superior outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"491\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143728\/KRAS-Inhibitors-Roadmap-1024x491.png\" alt=\"KRAS Inhibitors Roadmap\" class=\"wp-image-26628\" style=\"width:768px;height:368px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143728\/KRAS-Inhibitors-Roadmap-1024x491.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143728\/KRAS-Inhibitors-Roadmap-300x144.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143728\/KRAS-Inhibitors-Roadmap-150x72.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143728\/KRAS-Inhibitors-Roadmap-768x368.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143728\/KRAS-Inhibitors-Roadmap.png 1293w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Moreover, LUMAKRAS appears to have a more favorable safety profile compared to KRAZATI. Notably, KRAZATI is associated with QTc interval prolongation, a notable side effect that may elevate the risk of ventricular tachyarrhythmias. Despite LUMAKRAS showing potential advantages, drawing definitive conclusions remains challenging due to the overall similarity in the efficacy of both drugs. KRAZATI may offer increased utility, particularly for individuals with brain metastases, given that the lifetime incidence of brain metastases is approximately <strong>40%<\/strong> in patients with KRASG12C-mutant NSCLC.<\/p>\n\n\n\n<p>In the United States, Mirati\u2019s drug KRAZATI is priced at <strong>USD 19,750<\/strong> for a 30-day supply, whereas LUMAKRAS has a lower list price of <strong>USD 17,900<\/strong> per month. Sotorasib, with an estimated list price of <strong>GBP 6,907.35<\/strong> for a 30-day supply of 240 tablets (each containing 120 mg, excluding VAT and business submission), has a commercial arrangement in place (including a managed access agreement and a commercial access agreement). KRAZATI has not yet received licensing in Europe. LUMAKRAS 120 mg tablets are priced at approximately <strong>YEN 4,204.3 per tablet<\/strong>. Comparatively, current pricing indicates that in Japan and the UK, the prices are approximately <strong>60% and 50%<\/strong> lower than those in the US.<\/p>\n\n\n\n<p>Over <strong>40%<\/strong> of individuals with metastatic colorectal cancer exhibit a KRAS mutation, rendering them unresponsive to current targeted therapies such as EGFR inhibitors. <strong>Onvansertib <\/strong>holds substantial promise for this patient group due to its role as a PLK1 inhibitor, influencing downstream RAS pathways. This positions Onvansertib to potentially address the treatment requirements of all colorectal cancer patients with KRAS mutations.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/kras-inhibitors-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-1024x194.webp\" alt=\"KRAS Inhibitors infographic\" class=\"wp-image-26633\" style=\"width:768px;height:146px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08144025\/KRAS-Inhibitors-infographic.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Notably, alongside <strong>Amgen and Mirati Therapeutics<\/strong>, who are focused on the KRASG12C CRC subset, various other companies, including <strong>Novartis, Roche, InventisBio, Jacobio, Eli Lilly<\/strong>, and more, are exploring investigational drugs both as monotherapy and in combination with other targeted inhibitors. It is crucial to recognize that KRASG12C mutations represent only a small fraction of metastatic colorectal cancer cases, and fierce competition may limit commercial prospects. To capitalize on a substantial market share, it is essential to broaden the patient pool. <strong>Cardiff Oncology\u2019s Onvansertib<\/strong> is poised to exploit this opportunity, backed by robust clinical data in KRAS-mutant metastatic colorectal cancer. Additionally, Mirati Therapeutics is extending its focus beyond G12C with MRTX1133, specifically targeting <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\">G12D CRC patients<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-advancing-therapies-clinical-trials-for-kras-inhibitors\"><span class=\"ez-toc-section\" id=\"Advancing_Therapies_Clinical_Trials_for_KRAS_Inhibitors\"><\/span><strong>Advancing Therapies: Clinical Trials for KRAS Inhibitors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The G12C variant stands out as the most prevalent KRAS mutation in NSCLC. As a considerable number of drugs currently in the developmental pipeline are designed to target the G12C variant in NSCLC, the landscape is expected to become increasingly competitive. With the successful translation of KRASG12C discovery into clinical applications, attention has shifted towards the KRASG12D target, with <strong>Astellas <\/strong>emerging as a new player in this domain. Research efforts are now primarily concentrated on developing combination therapies aimed at preventing or overcoming resistance to KRASG12C inhibitors. Companies are also exploring pan-KRAS strategies to introduce tailored approaches for other KRAS mutation types.<\/p>\n\n\n\n<p>Preclinical and clinical evidence indicates that relying solely on a KRASG12C inhibitor as monotherapy may not be enough to achieve a sustained positive response. Therefore, combining KRASG12C inhibitors in therapy holds greater potential for demonstrating improved anti-tumor effectiveness and may also address adaptive resistance mechanisms. The majority of treatments are currently in the early stages of evaluation, with only a limited number progressing beyond Phase II.&nbsp;<\/p>\n\n\n\n<p>G12C is the most prominently targeted variant, although some treatments are exploring effectiveness against <strong>G12D, G12V, and G13D<\/strong>. Considerable attention is focused on the development of various allele-specific inhibitors, including those targeting G12V and G12R. Ongoing investigations involve combining KRAS inhibitors with immune checkpoint inhibitors, SHP2, SOS1, MEK inhibitors, and other agents to explore their effectiveness in addressing both initial and acquired resistance.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"921\" height=\"400\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143516\/Target-wise-KRAS-Inhibitors-Products-and-Their-Stage-of-Development.png\" alt=\"Target-wise KRAS Inhibitors Products and Their Stage of Development\" class=\"wp-image-26626\" style=\"width:691px;height:300px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143516\/Target-wise-KRAS-Inhibitors-Products-and-Their-Stage-of-Development.png 921w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143516\/Target-wise-KRAS-Inhibitors-Products-and-Their-Stage-of-Development-300x130.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143516\/Target-wise-KRAS-Inhibitors-Products-and-Their-Stage-of-Development-150x65.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143516\/Target-wise-KRAS-Inhibitors-Products-and-Their-Stage-of-Development-768x334.png 768w\" sizes=\"(max-width: 921px) 100vw, 921px\" \/><\/figure>\n\n\n\n<p>Some of the most <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">promising therapies in the pipeline targeting KRASG12C mutations<\/a> include <strong>JDQ443 (Novartis), Divarasib\/GDC-6036 (Roche), LY353798 (Eli Lilly)<\/strong>, and others. <strong>JDQ443 <\/strong>is an experimental compound that selectively targets and covalently binds to KRASG12C, and it is administered orally. Preliminary findings from the <strong>KontRASt-01 study (NCT04699188)<\/strong>, specifically from the Phase Ib stage, indicate a confirmed overall response rate (ORR) of 57% at the recommended dosage of 200 mg administered twice daily in patients with advanced NSCLC. Currently, the drug is undergoing Phase III trials, where it is being assessed as a monotherapy against docetaxel. This trial is focused on individuals with advanced NSCLC who carry a KRASG12C mutation and have previously undergone treatment with platinum-based chemotherapy and immune checkpoint inhibitor therapy, either sequentially or in combination. Novartis has plans to submit a New Drug Application (NDA) for JDQ443 by 2024 for the <a href=\"https:\/\/www.delveinsight.com\/blog\/recent-developments-in-nsclc-treatment\">treatment of NSCLC<\/a> and colorectal cancer following the year 2026.<\/p>\n\n\n\n<p><strong>Divarasib<\/strong>, also known as <strong>GDC-6036<\/strong>, is an orally administered small molecule. In preclinical models, it exhibited strong and specific inhibition of the KRAS G12C protein. GDC-6036 is specifically designed to bind selectively to the switch II pocket of the KRASG12C protein by interacting with the cysteine residue at position 12. This interaction leads to the irreversible locking of the protein in the inactive GDP-bound state. Results from the Phase Ib study of GDC-6036 in combination with cetuximab for colorectal cancer were presented at <strong>AACR 2023<\/strong>. The combined treatment of GDC-6036 and cetuximab demonstrated noteworthy clinical efficacy and a manageable safety profile in the treatment of CRC.<\/p>\n\n\n\n<p><strong>LY353798 <\/strong>is an exclusive covalent inhibitor designed for KRASG12C, displaying efficacy both as a standalone treatment and in conjunction with other anticancer therapies in preclinical models. Its competitive pharmacokinetic characteristics endorse its progression into clinical trials. In vitro studies have demonstrated its ability to target the KRAS G12C mutation, effectively hindering mutant KRAS-dependent signaling. LY353798 is currently undergoing investigation in a Phase I clinical trial involving patients with non-small cell lung cancer, colorectal cancer, or other advanced solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-lies-in-the-future-beyond-g12c\"><span class=\"ez-toc-section\" id=\"What_Lies_in_the_Future_Beyond_G12C\"><\/span><strong>What Lies in the Future Beyond G12C?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future of cancer therapies and treatment extends beyond the scope of KRASG12C mutations, marking a pivotal moment in the relentless pursuit of effective and personalized approaches to combat this formidable disease. While KRASG12C mutations have been a focal point in cancer research, ongoing advancements suggest a broader understanding of the intricate molecular landscape that underlies tumorigenesis.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td colspan=\"5\"><strong>A Brief Overview of KRAS Inhibition Beyond G12C&nbsp;<\/strong><\/td><\/tr><tr><td><strong>KRAS Target<\/strong><\/td><td><strong>Company<\/strong><\/td><td><strong>Product<\/strong><\/td><td><strong>Indication<\/strong><\/td><td><strong>Phase<\/strong><\/td><\/tr><tr><td rowspan=\"2\">PAN-KRAS<\/td><td>Cardiff Oncology<\/td><td>Onvansertip<\/td><td>CRC<\/td><td>Phase II<\/td><\/tr><tr><td>Gritstone Bio<\/td><td>SLATE-KRAS\/v2<\/td><td>NSCLC<\/td><td>Phase II<\/td><\/tr><tr><td>PAN-KRAS (except G12C)<\/td><td>Revolution Medicines<\/td><td>RMC-6236<\/td><td>NSCLC, CRC, PanC<\/td><td>Phase I<\/td><\/tr><tr><td>G12S, G12D, G12V<\/td><td>Immuneering<\/td><td>IMM\u20131-104<\/td><td>NSCLC, CRC, PanC<\/td><td>Phase II<\/td><\/tr><tr><td>G12D, G12R<\/td><td>Elicio Therapeutics<\/td><td>ELI-002-2P<\/td><td>CRC, PanC<\/td><td>Phase II<\/td><\/tr><tr><td rowspan=\"2\">G12D<\/td><td>Astellas<\/td><td>ASP3082<\/td><td>CRC, PanC<\/td><td>Phase I<\/td><\/tr><tr><td>Mirati<\/td><td>MRTX1133<\/td><td>NSCLC, CRC, PanC<\/td><td>Phase II<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>In recent years, the identification of additional genetic alterations and signaling pathways has opened new avenues for targeted therapies. Researchers are exploring novel targets beyond KRASG12C, seeking to decipher the complex interplay of genetic mutations that drive cancer progression. This multi-faceted approach acknowledges the heterogeneity of cancer and emphasizes the importance of tailored treatments based on individual molecular profiles.<\/p>\n\n\n\n<p>One promising avenue involves the development of combination therapies that target multiple signaling pathways simultaneously. By addressing the intricate network of genetic abnormalities, these combination strategies aim to enhance treatment efficacy and overcome potential resistance mechanisms. As our understanding of the genetic and molecular intricacies of cancer deepens, the prospect of more comprehensive and personalized therapeutic interventions becomes increasingly realistic.<\/p>\n\n\n\n<p>Furthermore, the integration of cutting-edge technologies, such as <a href=\"https:\/\/www.delveinsight.com\/blog\/top-applications-of-artificial-intelligence-in-healthcare\">artificial intelligence<\/a> and genomic sequencing, further propels the field towards precision medicine. Predictive modeling and analysis of vast datasets enable clinicians to identify optimal treatment strategies tailored to an individual\u2019s unique genetic makeup. This shift towards personalized medicine holds great promise for improving treatment outcomes and minimizing adverse effects.<\/p>\n\n\n\n<p>Therefore, the future beyond the KRASG12C mutation holds exciting prospects in the realm of cancer therapeutics. From expanding the scope of targeted therapies to exploring combinatorial approaches and harnessing the power of immunotherapy, researchers are at the forefront of a dynamic and evolving field. The ongoing efforts to unravel the intricacies of KRAS-mutant cancers pave the way for innovative treatments that may transform the outlook for patients facing these challenging diagnoses.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-untapped-potential-in-the-kras-inhibitors-market\"><span class=\"ez-toc-section\" id=\"Untapped_Potential_in_the_KRAS_Inhibitors_Market\"><\/span><strong>Untapped Potential in the KRAS Inhibitors Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The treatment landscape for KRAS-mutant cancers has rapidly evolved, with several promising advancements in recent years. The KRAS inhibitor market is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments; ongoing research and clinical trials have identified potential treatment strategies.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">market size for KRAS inhibitors<\/a> reached <strong>USD 240 million<\/strong> in 2022 across the 7MM and is expected to grow with a significant CAGR to reach <strong>USD 10 billion<\/strong> by 2032. As per the estimates, the US is set to be the largest market for KRAS inhibitors, with <strong>~70%<\/strong> of the market share among the seven major markets.<\/p>\n\n\n\n<p>NSCLC is anticipated to emerge as the predominant market for therapies targeting KRAS, driven by heightened interest from major pharmaceutical and biotech companies in exploring untapped KRAS biomarkers, particularly G12C variants. <strong>Mirati Therapeutics and Amgen<\/strong>, with their G12C inhibitors <strong>KRAZATI and LUMAKRAS<\/strong>, respectively, are poised to achieve blockbuster status in the coming years as key players in the KRAS inhibitors market.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"521\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143812\/Launch-Timeline-of-KRAS-inhibitors-across-various-indications-1024x521.png\" alt=\"Launch Timeline of KRAS inhibitors across various indications\" class=\"wp-image-26629\" style=\"width:768px;height:391px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143812\/Launch-Timeline-of-KRAS-inhibitors-across-various-indications-1024x521.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143812\/Launch-Timeline-of-KRAS-inhibitors-across-various-indications-300x153.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143812\/Launch-Timeline-of-KRAS-inhibitors-across-various-indications-150x76.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143812\/Launch-Timeline-of-KRAS-inhibitors-across-various-indications-768x391.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143812\/Launch-Timeline-of-KRAS-inhibitors-across-various-indications.png 1134w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Subsequent to NSCLC, colorectal cancer exhibits notable pipeline activity, featuring companies such as <strong>Novartis (JDQ443), Roche (Divarasib), InventisBio (D-1553), Jacobio (Glecirasib), and Eli Lilly (LY3537982)<\/strong>. Cardiff Oncology is positioned as a market leader in <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\">colorectal cancer treatment<\/a> with its PLK1-inhibiting drug Onvansertib for KRAS-mutated CRC. Despite KRAS being more prevalent in pancreatic cancer than in colorectal cancer and NSCLC, there is limited pipeline activity in this area. Anticipated growth in the KRAS pancreatic cancer category over the next decade is restrained, primarily due to the majority of experimental medicines being in the early stages of research.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-a-glimpse-into-the-future\"><span class=\"ez-toc-section\" id=\"Conclusion_A_Glimpse_into_the_Future\"><\/span><strong>Conclusion: A Glimpse into the Future<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers. The progress made in decoding the complexities of KRAS and the development of targeted inhibitors underscores the resilience of scientific innovation in confronting challenging diseases.<\/p>\n\n\n\n<p>As research in this field advances, the future holds the promise of more refined therapies, improved patient outcomes, and potentially transforming the <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/cancer-treatment-through-novel-biomarkers\">landscape of cancer treatment<\/a>. The pursuit of effective KRAS inhibitors stands as a testament to the relentless efforts of the scientific community in combating cancer and bringing forth a new era of precision medicine.<\/p>\n\n\n\n<p>In the dynamic landscape of cancer research, the quest for more potent KRAS inhibitors remains a beacon of hope, illuminating the path toward more effective and personalized cancer treatments.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--1024x256.png\" alt=\"KRAS Inhibitors Market Outlook \" class=\"wp-image-26624\" style=\"width:768px;height:192px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook--1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08143103\/KRAS-Inhibitors-Market-Outlook-.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Frequently Asked Questions<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1758864760462\"><strong class=\"schema-faq-question\"><strong>What is the significance of KRAS G12C mutation vs other KRAS variants like G12D, G12V?<\/strong><\/strong> <p class=\"schema-faq-answer\">The G12C mutation has been the most studied and targeted (especially in non-small cell lung cancer), and drugs like sotorasib and adagrasib act by binding specifically to the mutated cysteine in G12C. However, variants like G12D, G12V, G13D are more frequent in other cancers such as colorectal and pancreatic cancer, yet have fewer approved therapies or effective inhibitors to date.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864773235\"><strong class=\"schema-faq-question\"><strong>What are \u201cpan-KRAS\u201d and non-G12C selective inhibitors, and are there any promising candidates in the pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">Pan-KRAS inhibitors are designed to target multiple KRAS variants (not just G12C). Examples in the pipeline include Onvansertib (for colorectal cancer), RMC-6236, IMM-1-104, ELI-002-2P, Astellas\u2019s ASP3082, and Mirati\u2019s MRTX1133 targeting G12D. These are in various clinical trial phases (Phase I\/II) and aim to broaden treatment beyond G12C.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864783924\"><strong class=\"schema-faq-question\"><strong>How big is the KRAS inhibitors market, and what are the growth projections?<\/strong><\/strong> <p class=\"schema-faq-answer\">In 2025, the market size for KRAS inhibitors across the seven major markets (7MM) was about USD 526 million. It is expected to grow substantially, reaching around USD 7,487 million by 2034 at a <strong>CAGR of 35%<\/strong> as more inhibitors (beyond G12C) enter clinical use.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864868322\"><strong class=\"schema-faq-question\"><strong>What challenges or resistance issues are associated with G12C inhibitors?<\/strong><\/strong> <p class=\"schema-faq-answer\">Even though G12C inhibitors demonstrate good efficacy, resistance mechanisms emerge\u2014some tumors can bypass KRAS G12C inhibition via alternative activation of PI3K or MAPK pathways. Also, therapies may have limited brain penetration or adverse effects (e.g., QTc prolongation for some). That\u2019s prompting combination strategies (e.g., pairing KRAS inhibitors with MEK inhibitors, SHP2 inhibitors, immune checkpoint blockade) to overcome resistance.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864879360\"><strong class=\"schema-faq-question\"><strong>What does the future look like beyond G12C? What is needed for non-G12C KRAS mutation targeting to succeed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Success beyond G12C depends on development of allele-specific inhibitors (for G12D, G12V, etc.), better biomarker-driven patient selection, combining therapies to prevent resistance, and early-stage clinical advancements. Also, there\u2019s need for therapies targeting KRAS in cancers with high prevalence of non-G12C variants \u2014 e.g., pancreatic and colorectal cancers. Increased investment, novel drug design, and supportive regulatory environments will be crucial<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a bond with cysteine 12 in the KRAS-G12C protein\u2019s [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":26621,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1837,906,21634,17026,21632,21633,19862,21631,21635,19013,21630,1111,19011],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-26620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-artificial-intelligence","tag-cancer-therapies","tag-colorectal-cancer-treatment","tag-kras-inhibitors","tag-kras-inhibitors-market","tag-kras-inhibitors-market-size","tag-kras-mutated-cancers","tag-krasg12c-mutations","tag-krazati","tag-lumakras","tag-metastatic-colorectal-cancer-treatment","tag-nsclc","tag-nsclc-treatment","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Future of KRAS Targeting Cancer Therapies Beyond G12C<\/title>\n<meta name=\"description\" content=\"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Future of KRAS Targeting Cancer Therapies Beyond G12C\" \/>\n<meta property=\"og:description\" content=\"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-08T12:42:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-26T05:34:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Future of KRAS Targeting Cancer Therapies Beyond G12C","description":"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","og_locale":"en_US","og_type":"article","og_title":"The Future of KRAS Targeting Cancer Therapies Beyond G12C","og_description":"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.","og_url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-01-08T12:42:01+00:00","article_modified_time":"2025-09-26T05:34:59+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","name":"The Future of KRAS Targeting Cancer Therapies Beyond G12C","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","datePublished":"2024-01-08T12:42:01+00:00","dateModified":"2025-09-26T05:34:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864760462"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864773235"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864783924"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864868322"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864879360"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","width":1200,"height":800,"caption":"kras-inhibitors-beyond-g12c"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864760462","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864760462","name":"What is the significance of KRAS G12C mutation vs other KRAS variants like G12D, G12V?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The G12C mutation has been the most studied and targeted (especially in non-small cell lung cancer), and drugs like sotorasib and adagrasib act by binding specifically to the mutated cysteine in G12C. However, variants like G12D, G12V, G13D are more frequent in other cancers such as colorectal and pancreatic cancer, yet have fewer approved therapies or effective inhibitors to date.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864773235","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864773235","name":"What are \u201cpan-KRAS\u201d and non-G12C selective inhibitors, and are there any promising candidates in the pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Pan-KRAS inhibitors are designed to target multiple KRAS variants (not just G12C). Examples in the pipeline include Onvansertib (for colorectal cancer), RMC-6236, IMM-1-104, ELI-002-2P, Astellas\u2019s ASP3082, and Mirati\u2019s MRTX1133 targeting G12D. These are in various clinical trial phases (Phase I\/II) and aim to broaden treatment beyond G12C.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864783924","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864783924","name":"How big is the KRAS inhibitors market, and what are the growth projections?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"In 2025, the market size for KRAS inhibitors across the seven major markets (7MM) was about USD 526 million. It is expected to grow substantially, reaching around USD 7,487 million by 2034 at a <strong>CAGR of 35%<\/strong> as more inhibitors (beyond G12C) enter clinical use.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864868322","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864868322","name":"What challenges or resistance issues are associated with G12C inhibitors?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Even though G12C inhibitors demonstrate good efficacy, resistance mechanisms emerge\u2014some tumors can bypass KRAS G12C inhibition via alternative activation of PI3K or MAPK pathways. Also, therapies may have limited brain penetration or adverse effects (e.g., QTc prolongation for some). That\u2019s prompting combination strategies (e.g., pairing KRAS inhibitors with MEK inhibitors, SHP2 inhibitors, immune checkpoint blockade) to overcome resistance.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864879360","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864879360","name":"What does the future look like beyond G12C? What is needed for non-G12C KRAS mutation targeting to succeed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Success beyond G12C depends on development of allele-specific inhibitors (for G12D, G12V, etc.), better biomarker-driven patient selection, combining therapies to prevent resistance, and early-stage clinical advancements. Also, there\u2019s need for therapies targeting KRAS in cancers with high prevalence of non-G12C variants \u2014 e.g., pancreatic and colorectal cancers. Increased investment, novel drug design, and supportive regulatory environments will be crucial","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">artificial intelligence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">colorectal cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS inhibitors market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS inhibitors market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS-mutated cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRASG12C mutations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAZATI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lumakras<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">metastatic colorectal cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NSCLC treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">artificial intelligence<\/span>","<span class=\"advgb-post-tax-term\">Cancer therapies<\/span>","<span class=\"advgb-post-tax-term\">colorectal cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">KRAS Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">KRAS inhibitors market<\/span>","<span class=\"advgb-post-tax-term\">KRAS inhibitors market size<\/span>","<span class=\"advgb-post-tax-term\">KRAS-mutated cancers<\/span>","<span class=\"advgb-post-tax-term\">KRASG12C mutations<\/span>","<span class=\"advgb-post-tax-term\">KRAZATI<\/span>","<span class=\"advgb-post-tax-term\">Lumakras<\/span>","<span class=\"advgb-post-tax-term\">metastatic colorectal cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">NSCLC treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Jan 8, 2024","modified":"Updated on Sep 26, 2025"},"absolute_dates_time":{"created":"Posted on Jan 8, 2024 6:12 pm","modified":"Updated on Sep 26, 2025 11:04 am"},"featured_img_caption":"kras-inhibitors-beyond-g12c","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26620"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26620\/revisions"}],"predecessor-version":[{"id":33481,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26620\/revisions\/33481"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26621"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26620"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26620"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}